Table 2. Salvage focal brachytherapy outcomes.
| Author | Year | n | Median age (years) | Median pre-salvage PSA (ng/mL) | Median follow-up (months) | Biochemical disease-free survival | Metastasis | Conversion to second-line salvage therapies |
|---|---|---|---|---|---|---|---|---|
| Hsu et al. (39) | 2013 | 15 | 68 | 3.5 | 23.3 | 100% (2 years); 71.4% (3 years) | 0% | 13.3% (focal sBT: 2) |
| Peters et al. (40) | 2014 | 20 | 69 | 4.7 | 36 | 71% (3 years) | 15% | 30.0% (ADT: 6) |
| Kunogi et al. (41) | 2016 | 12 | 68 | 4.1 | 56 | 78% (4 years) | 0% | 16.7% (ADT: 1, WW: 1) |
| Maenhout et al. (42) | 2017 | 17 | 69 | 4.8 | 10 | 92% (2 years) | 5.9% | n.a. |
| Murgic et al. (43) | 2018 | 15 | 75 | 4.1 | 36 | 87% (2 years); 61% (3 years) | 0% | n.a. |
PSA, prostate-specific antigen; sBT, salvage brachytherapy; ADT, androgen deprivation therapy; WW, watchful waiting; n.a., not available.